South Korea · Delayed Price · Currency is KRW HYUNDAI BIOLAND Statistics
Total Valuation
HYUNDAI BIOLAND has a market cap or net worth of KRW 133.95 billion. The enterprise value is 136.00 billion.
| Market Cap | 133.95B |
| Enterprise Value | 136.00B |
Important Dates
The last earnings date was Monday, August 4, 2025.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
HYUNDAI BIOLAND has 30.00 million shares outstanding. The number of shares has increased by 14.28% in one year.
| Current Share Class | 30.00M |
| Shares Outstanding | 30.00M |
| Shares Change (YoY) | +14.28% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 0.75% |
| Float | 19.50M |
Valuation Ratios
The trailing PE ratio is 10.72 and the forward PE ratio is 7.32.
| PE Ratio | 10.72 |
| Forward PE | 7.32 |
| PS Ratio | 1.06 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 1.02 |
| P/FCF Ratio | 53.00 |
| P/OCF Ratio | 19.19 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 6.34, with an EV/FCF ratio of 53.81.
| EV / Earnings | -33.77 |
| EV / Sales | 1.08 |
| EV / EBITDA | 6.34 |
| EV / EBIT | 8.68 |
| EV / FCF | 53.81 |
Financial Position
The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.08.
| Current Ratio | 3.86 |
| Quick Ratio | 1.48 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 4.21 |
| Interest Coverage | 30.52 |
Financial Efficiency
Return on equity (ROE) is 9.02% and return on invested capital (ROIC) is 6.09%.
| Return on Equity (ROE) | 9.02% |
| Return on Assets (ROA) | 5.61% |
| Return on Invested Capital (ROIC) | 6.09% |
| Return on Capital Employed (ROCE) | 11.53% |
| Revenue Per Employee | 370.02M |
| Profits Per Employee | -11.81M |
| Employee Count | 341 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.50 |
Taxes
In the past 12 months, HYUNDAI BIOLAND has paid 1.44 billion in taxes.
| Income Tax | 1.44B |
| Effective Tax Rate | 10.34% |
Stock Price Statistics
The stock price has decreased by -13.63% in the last 52 weeks. The beta is 0.88, so HYUNDAI BIOLAND's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -13.63% |
| 50-Day Moving Average | 4,639.50 |
| 200-Day Moving Average | 4,669.38 |
| Relative Strength Index (RSI) | 40.30 |
| Average Volume (20 Days) | 104,066 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HYUNDAI BIOLAND had revenue of KRW 126.18 billion and -4.03 billion in losses. Loss per share was -134.25.
| Revenue | 126.18B |
| Gross Profit | 55.07B |
| Operating Income | 15.67B |
| Pretax Income | 13.94B |
| Net Income | -4.03B |
| EBITDA | 21.44B |
| EBIT | 15.67B |
| Loss Per Share | -134.25 |
Balance Sheet
The company has 8.59 billion in cash and 10.64 billion in debt, giving a net cash position of -2.05 billion or -68.18 per share.
| Cash & Cash Equivalents | 8.59B |
| Total Debt | 10.64B |
| Net Cash | -2.05B |
| Net Cash Per Share | -68.18 |
| Equity (Book Value) | 134.65B |
| Book Value Per Share | 4,488.31 |
| Working Capital | 60.39B |
Cash Flow
In the last 12 months, operating cash flow was 6.98 billion and capital expenditures -4.45 billion, giving a free cash flow of 2.53 billion.
| Operating Cash Flow | 6.98B |
| Capital Expenditures | -4.45B |
| Free Cash Flow | 2.53B |
| FCF Per Share | 84.25 |
Margins
Gross margin is 43.65%, with operating and profit margins of 12.42% and -3.19%.
| Gross Margin | 43.65% |
| Operating Margin | 12.42% |
| Pretax Margin | 11.05% |
| Profit Margin | -3.19% |
| EBITDA Margin | 16.99% |
| EBIT Margin | 12.42% |
| FCF Margin | 2.00% |
Dividends & Yields
This stock pays an annual dividend of 35.00, which amounts to a dividend yield of 0.79%.
| Dividend Per Share | 35.00 |
| Dividend Yield | 0.79% |
| Dividend Growth (YoY) | 100.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -14.28% |
| Shareholder Yield | -13.49% |
| Earnings Yield | -3.01% |
| FCF Yield | 1.89% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a forward split with a ratio of 2.
| Last Split Date | May 17, 2024 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
HYUNDAI BIOLAND has an Altman Z-Score of 6.42 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.42 |
| Piotroski F-Score | 5 |